<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00411125</url>
  </required_header>
  <id_info>
    <org_study_id>CSMC021A2111</org_study_id>
    <nct_id>NCT00411125</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Pharmacodynamics Study of Oral Salmon Calcitonin in Healthy Postmenopausal Women</brief_title>
  <official_title>A Double-Blind, Double-Dummy, Randomized, Placebo-Controlled Crossover Phase I Study Assessing Pharmacokinetics and Pharmacodynamics of Two Different SMC021 0.8 mg Variants and the Effect of Timing of Drug Intake in Healthy Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This is a phase I study to analyze bioavailability and pharmacodynamic of two different
      variants of oral salmon calcitonin (SMC021) in postmenopausal women
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date>November 2006</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic profile of the new variant compared to the current variant on Day 1</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect on bone resorption biomarker on Day 1</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect on bone resorption biomarker 24 hours after the last dosing on Day 3</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on bone resorption biomarker after drug intake at different timepoints</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of dosing at different timepoints on the pharmacokinetic profile</measure>
  </secondary_outcome>
  <enrollment>86</enrollment>
  <condition>Postmenopausal Osteoporosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral salmon calcitonin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy postmenopausal women

        Exclusion Criteria:

          -  Previous treatment with other osteoporosis medication

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis Basel</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Basel +41 61 324 1111</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2006</study_first_submitted>
  <study_first_submitted_qc>December 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2006</study_first_posted>
  <last_update_submitted>December 11, 2006</last_update_submitted>
  <last_update_submitted_qc>December 11, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2006</last_update_posted>
  <keyword>Postmenopausal</keyword>
  <keyword>osteoporosis</keyword>
  <keyword>Pharmacokinetics/dynamics</keyword>
  <keyword>Calcitonin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Salmon calcitonin</mesh_term>
    <mesh_term>Calcitonin</mesh_term>
    <mesh_term>Calcitonin Gene-Related Peptide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

